Estadístiques de Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach
Visites totals
| views | |
|---|---|
| Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach | 116 |
Visites totals per mes
| views | |
|---|---|
| July 2024 | 0 |
| August 2024 | 3 |
| September 2024 | 15 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Carcereny_onc_head.pdf(legacy) | 74 |
| Carcereny_onc_head.pdf | 2 |
Vistes principals per país
| views | |
|---|---|
| United States | 86 |
| Spain | 10 |
| Canada | 5 |
| Ireland | 3 |
| Sweden | 3 |
| Czechia | 2 |
| Belgium | 1 |
| China | 1 |
| United Kingdom | 1 |
| Italy | 1 |
| Japan | 1 |
| Malaysia | 1 |
| Senegal | 1 |
Visites principals per ciutat
| views | |
|---|---|
| San Ramon | 25 |
| Boardman | 11 |
| San Mateo | 10 |
| Barcelona | 8 |
| Ann Arbor | 6 |
| Fairfield | 6 |
| Toronto | 5 |
| Ashburn | 4 |
| Cambridge | 4 |
| Mountain View | 4 |
| Dublin | 3 |
| Menlo Park | 3 |
| Arteixo | 1 |
| Durham | 1 |
| Los Vargas | 1 |
| Petaling Jaya | 1 |
| Redwood City | 1 |
| San Diego | 1 |
| Tokyo | 1 |